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A B S T R A C T
Background: In BIOACTIVE study, we evaluated vascular responses after the implant of biolimus A9-eluting 
stent (BES; BioMatrixTM) and the everolimus-eluting stent (EES; XIENCE VTM). In this study, we present the 
optical coherence tomography analysis (OCT) 6 months post-intervention.
Methods: Patients were randomized to treatment with BES (n = 22) or EES (n = 18). The primary outcome 
was the frequency of non-covered, poorly positioned struts by OCT.
Results: OCT was performed in 26 patients (BES: n = 15; EES: n = 11) and 749 tomographic images and 7,725 
stent struts were analyzed. BES and EES showed similar luminal and stent areas. Neointimal hyperplasia 
area, neointimal thickness and the percentage of in-stent obstruction (8.44 ± 5.10% vs. 9.21 ± 6.36%; p = 
0.74) were similar. The rates of not covered struts (BES: 2.10 ± 3.60% vs. ESS: 2.46 ± 2.15%, p = 0.77) and 
poorly positioned struts (BES: 0.48 ± 1.48% vs. EES 0.44 ± 1.05%, p = 0.94) were similarly low. The frequency 
of frames with signs consistent with peri-strut inflammatory infiltrate was low and similar between BES 
(15.53 ± 20.77%) and EES (11.70 ± 27.51%; p = 0.68).
Conclusions: The second-generation drug-eluting stents BES and EES were equally effective at suppressing 
the neointimal formation after 6 months, with favorable vascular responses. The frequency of frames 
with peri-strut infiltrate signals per patient was low, and lower than that observed historically with first-
generation drug-eluting stents.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Resposta vascular após implante de stents liberadores de biolimus A9  
com polímero bioabsorvível e stents liberadores de everolimus com polímero 
durável. Resultados da análise de tomografia de coerência óptica do estudo 
randomizado BIOACTIVE
R E S U M O
Introdução: No estudo BIOACTIVE, avaliamos as respostas vasculares após implante do stent eluidor de 
biolimus A9 (SEB; BioMatrixTM) e o stent eluidor de everolimus (SEE; XIENCE VTM). Apresentamos a análise 
de tomografia de coerência óptica (OCT) 6 meses pós-intervenção.
Métodos: Os pacientes foram randomizados para tratamento com SEB (n = 22) ou SEE (n = 18). O desfecho 
primário foi a frequência de hastes não cobertas e mal apostas pela OCT.
Resultados: A OCT foi realizada em 26 pacientes (SEB: n = 15; SEE: n = 11) e foram analisadas 749 imagens 
tomográficas e 7.725 hastes de stent. SEB e SEE apresentaram áreas luminais e dos stents semelhantes. 
A área de hiperplasia neointimal, a espessura neointimal e o porcentual de obstrução intra-stent (8,44 
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± 5,10% vs. 9,21 ± 6,36%; p = 0,74) foram similares. As taxas de hastes não cobertas (SEB: 2,10 ± 3,60% vs. 
SEE: 2,46 ± 2,15%; p = 0,77) e mal apostas (SEB: 0,48 ± 1,48% vs. SEE 0,44 ± 1,05%; p = 0,94) foram baixas e 
semelhantes. A frequência de frames com sinais compatíveis com infiltrado inflamatório peri-haste foi 
baixa e similar entre SEB (15,53 ± 20,77%) e SEE (11,70 ± 27,51%; p = 0,68).
Conclusões: Stents farmacológicos de segunda geração SEB e SEE se mostraram igualmente eficientes em 
suprimir a formação neointimal aos 6 meses, com respostas vasculares favoráveis. A frequência de frames 
com sinais de infiltrado peri-haste por paciente foi baixa, e menor do que a historicamente observada com 
os stents farmacológicos de primeira geração.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Drug-eluting stents (DES), designed under the concept of locally 
applying an antiproliferative agent on the vascular wall in a con-
trolled manner, have met their primary endpoint of reducing exces-
sive neointimal formation, commonly observed after coronary 
angioplasty with balloon and bare-metal stent (BMS) implanta-
tion.1,2 High antiproliferative efficacy has resulted in a significant 
reduction in restenosis rates and need for new coronary revascular-
ization in a wide variety of clinical and anatomical scenarios,3-8 
making DES implantation the standard treatment strategy during 
percutaneous coronary intervention (PCI) procedures in many re-
gions of the world.
However, the widespread use of DES and longer follow-up of pa-
tients treated with this technology disclosed a significantly higher 
incidence of late- and very-late thrombosis than in those seen after 
BMS implantation.9-11
Although late/very late stent thrombosis is a multifactorial phe-
nomenon, incomplete strut coverage due to delay in cellular matrix 
and functioning endothelium formation, chronic inflammatory re-
actions in the vessel wall, vascular remodeling, and acquired late 
malapposition were demonstrated after the implantation of first-
generation DES.12-16 In general, these DES consisted of stainless steel 
platforms with relatively thick metal struts that eluted high doses of 
sirolimus or paclitaxel via durable polymeric carriers distributed 
around the entire metal surface. In particular, the durable polymers 
of the first-generation DES – in permanent contact with the vessel 
wall – were associated with local hypersensitivity reactions.12
These findings led to the development of new DES, aiming to re-
duce toxicity to the vascular wall and increase the biocompatibility 
of these devices, although without losing the antiproliferative effi-
cacy displayed by the first-generation DES. In this sense, a number of 
modifications were implemented: platforms made of new metallic 
alloys; thinner struts; improved delivery systems; new antiprolifer-
ative drugs; use of lower doses of drugs; new polymeric matrices 
that are thinner, more biocompatible, and even bioresorbable; poly-
mer applied directly to the abluminal side of the stent struts; and 
drug carrying and elution by non-polymeric platforms, etc.17
The BIOACTIVE study aimed to assess vascular responses after 
implantation of two second generation DES – BioMatrixTM (biolimus 
A9-eluting stent, utilizing a biodegradable polymer), and XIENCE 
VTM (everolimus-eluting stent, utilizing a durable, biocompatible 
fluoropolymer), which incorporated one or more of the aforemen-
tioned characteristics. For that purpose, optical coherence tomogra-
phy (OCT) images were used, which, through high-resolution CT 
images, allow accurate assessment of the vascular repair process 
after coronary stenting.18,19 This study aimed to present the OCT 
analysis at 6 months post-intervention.
Methods
Study design and population
BIOACTIVE is a prospective, randomized trial of the investigators’ 
initiative, in two centers (Instituto Dante Pazzanese de Cardiologia 
and Hospital Santa Marcelina), located in São Paulo, SP, Brazil, which 
aimed to assess the coronary vascular response six months after the 
implantation of the second-generation XIENCE VTM and BioMatrixTM 
DES. The primary endpoint of the study consisted of the combined 
assessment of two outcomes after six months: 1– evaluation of coro-
nary endothelial function – quantified by quantitative coronary an-
giography (QCA) through changes in the peri-stent luminal diameter 
(5 mm proximal and distal to the stent borders) between periods of 
rest, during sequential stimulation with cardiac pacemaker, and af-
ter administration of intracoronary nitroglycerin; and 2– quantifica-
tion of the percentage coverage of the stent struts through OCT. 
Secondary endpoints consisted of the assessment of efficacy through 
QCA, intravascular ultrasound (IVUS), and OCT in the invasive 
6 month follow-up.
Patients with de novo coronary lesions, with a maximum length 
of 20 mm and located in native coronary arteries with a diameter of 
3.0 mm to 3.5 mm, were included in the study. Diabetic patients 
were excluded, as well as patients treated within 72 hours of an 
acute myocardial infarction (AMI) with ST-segment elevation. Pa-
tients with renal failure (serum creatinine > 2.0 mg/dL or estimated 
creatinine clearance < 30 mL/min) or severe left ventricular dysfunc-
tion (left ventricular ejection fraction < 30%) were also excluded. The 
main angiographic exclusion criteria were ostial lesions, bifurcation 
lesions, lesions in the left main coronary artery, or with the presence 
of thrombi or significant calcification.
The BIOACTIVE study was approved by the Research Ethics Com-
mittee of the participating institutions, and all patients signed an 
informed consent before randomization.
Characteristics of assessed stents
The BioMatrixTM stent has a stainless steel platform, 120 m 
thick struts, coated with a 10 m thick durable primer (parylene 
C) and an 11 m thick polylactic acid (PLA) polymer, distributed 
only on the abluminal surface of the struts. This polymer carries 
the antiproliferative drug biolimus A9 and is designed to perform 
an initial fast release of approximately 40% of the drug. Subse-
quently, it is co-released with the remaining drug over a period of 
6 to 9 months. Finally, the polymer is degraded into carbon diox-
ide and water.
The XIENCE VTM stent consists of a cobalt-chromium platform 
with thin struts (81 m), coated with a durable and highly biocom-
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patible fluoropolymer, distributed around the entire surface of the 
struts. This polymer carries the antiproliferative drug everolimus at 
a dose of 100 m/mm2 and is designed to release 80% of the total 
drug dose in the first 30 days after implantation.
Procedures
PCI procedures were performed according to the routines of the 
institutions and in accordance with current recommendations.20,21 
Pre-treatment with acetylsalicylic acid loading dose (300 mg) and 
clopidogrel (300 or 600 mg) was administered at least 24 hours be-
fore PCI to patients who were not chronic users of these medica-
t ions. At the start of the procedure, anticoagulation with 
unfractionated heparin (100 IU/kg) was carried out with administra-
tion of additional bolus, where necessary, to maintain an activated 
clotting time ≥ 250 seconds.
After adequate positioning of the 0.014’’ guidewire in the distal 
portion of the target vessel, patients were randomized in a 1:1 
proportion to receive the BioMatrixTM or XIENCE VTM stents. Predila-
tion of target lesions was not mandatory and the direct stenting was 
allowed. The indication for stent post-dilation was made at the oper-
ating physician’s discretion and, when performed, was done with 
balloons, preferably noncompliant, with a shorter length than the 
nominal length of the implanted stent, in order to prevent inflations 
out of the treated segment.
Follow-up and endpoints
All patients were assessed by clinical consultation at the medical 
office or by telephone calls at 1; 6 and 12 months after the index PCI. 
Angiographic restudy, with IVUS and OCT, was performed after 6 
months.
The present analysis shows the comparison of vascular response 
assessment by OCT, for which the primary endpoint was the differ-
ence in the percentage of struts not covered by neointimal tissue in 
both treatment groups. The secondary outcomes of the OCT analysis 
were as follows: frequency of strut malapposition, neointimal tissue 
area, percentage of stent obstruction by neointimal tissue, and neo-
intimal thickness. The occurrence of major adverse cardiac events 
(death, nonfatal myocardial revascularization, and target-vessel re-
vascularization) at 12 months was also computed as a secondary 
outcome.
All adverse events were adjudicated and classified by an indepen-
dent adjudication committee blinded to the type of stent received by 
patients.
Acquisition and analysis of optical coherence tomography images
The OCT images were acquired with the commercially available 
time-domain OCT system (M3 System; LightLab Imaging, Westford, 
USA) or frequency-domain optical coherence tomography system 
(C7 XR; St. Jude Medical, St. Paul, USA). The techniques used for im-
age acquisition with both OCT systems have been previously de-
scribed in detail.22,23 All images were stored in digital media and 
sent for analysis to an independent central laboratory (Cardiovascu-
lar Research Center, São Paulo, SP, Brazil). Analyses were performed 
using a dedicated and previously validated program24 (QIvusTM, ver-
sion 3.0; Medis Medical Imaging, Leiden, Netherlands) and the op-
erating physicians were blinded to the type of stent received by 
each patient.
After adjusting for the different pullback velocities of the imaging 
catheter provided by the two types of OCT equipment used, the 
analyses of tomographic vessel images were made at 0.6 mm inter-
vals in the longitudinal direction, along the entire treated segment.
Automatic segmentation of the luminal contour (border between 
the lumen and the vessel intimal layer) was performed by the analy-
sis program inside the predetermined segment, with manual adjust-
ments made if necessary. Metal stent struts appear on the OCT as 
small points, or rounded or tapered structures that promote high 
reflection of the light signal emitted by the OCT catheter (blooming) 
and dorsal shadowing. Thus, a strut was considered for analysis only 
when the blooming + dorsal shadowing binomial was present. An 
automatic strut detection algorithm was used; false-positive or 
false-negative corrections were performed manually. The number of 
struts analyzed in each cross-sectional image along the segment of 
interest was then automatically computed. The contour traced along 
the inner surface of each strut was performed automatically and de-
fined the stent area in each analyzed frame. Finally, the distance be-
tween the central points of the luminal face of each strut to the 
luminal contour was determined automatically by lines directed 
towards the center of gravity of the vessel (Fig. 1). When this dis-
tance was positive, the struts were classified as covered. Positive 
values of the distance between the stent strut and the lumen con-
tour determined neointimal thickness in each individual strut. In 
case of negative distances, the struts were classified as uncovered 
(Fig. 2). If the negative distance was greater than the sum of the 
thickness of the strut + the thickness of the polymer (when present) 
+ a correction factor for the minimum axial resolution of the OCT, 
the strut was classified as malapposed. Therefore, the cut-off points 
used to define strut malapposition varied according to the charac-
teristics of each stent (BioMatrixTM = 150 m and XIENCE VTM = 
110 m) (Fig. 3).
The neointimal area was determined based on the measurement 
of the neointimal thickness, located between the stent and luminal 
contour. Regions around the vessel circumference, with a negative 
distance between the stent and the lumen contours (no tissue cover-
age), were included for neointimal quantification (Fig. 3). After the 
Figure 1. Optical coherence tomography analysis. The luminal contour is segmented 
automatically, following the border between the lumen and the intimal layer (red 
line). Then the stent struts – highly light-reflective structures, with dorsal shade – are 
identified by an automated algorithm. The points located on the luminal surface are 
connected to determine the stent area (pink line). The distances between the luminal 
surface of each strut to the luminal contour are automatically determined by a trajec-
tory directed towards the center of the vessel (green lines).
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neointimal area was determined, stent obstruction percentage was 
computed for each analyzed frame by dividing the neointimal area 
by the stent area. The homogeneity of the circumferential and longi-
tudinal distribution of neointimal hyperplasia along the treated seg-
ment was evaluated by visual assessment of scatter plots created for 
each case.
Finally, a qualitative assessment of neointimal tissue formed over 
the stent struts was performed. Peri-strut infiltrate regions were de-
fined as homogeneous areas reflecting the optical signal with less 
intensity than the adjacent tissue, but without causing light attenu-
ation.25 Neoatherosclerosis was defined as the presence of lipid infil-
trate or neointimal calcification.26 Figure 4 illustrates examples of 
qualitative assessment of neointimal tissue formed over the stent 
struts.
Statistical analysis
Statistical analyses were performed using SPSS, version 20.0 (IBM 
Corp., Armonk, USA), and R software, version 3.1.1 (The R Foundation 
for Statistical Computing, Vienna, Austria).
Continuous variables are shown as mean and standard deviation 
and categorical variables as frequency and percentage. Categorical 
variables were analyzed by chi-squared test or Fisher’s exact test, 
and continuous variables by Student’s t-test and Mann-Whitney U-
test, depending on variable distribution.
A generalized estimating equations model with first-order au-
toregressive covariance structure was used to adjust the analyses 
according to the pooled nature of the data from each patient (for in-
stance, a patient with a stent placed in one vessel has dozens of 
frames and hundreds of struts analyzed). Thus, for a patient who re-
ceived a long stent with more frames and struts analyzed, a different 
weight was computed as compared to another patient who received 
a short stent with fewer frames and struts analyzed.
All analyses were two-tailed and p < 0.05 was considered statisti-
cally significant.
Results
Characteristics of the population and procedures
Between July 2011 and April 2012, a total of 40 patients were 
included in the BIOACTIVE trial and randomized to receive the Bio-
A B C
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Figure 2. Strut coverage pattern. Each stent strut – present in each frame analyzed at 
0.6 mm intervals from the treated segment – was evaluated. When the distance be-
tween the central point of the strut on its luminal surface in relation to the contour of 
the vascular lumen was positive, the strut was classified as covered, and the tissue 
thickness was determined by the distance in micrometers (panels A and B). When the 
distance was negative, the struts were classified as non-covered (panels C and D). If 
this negative distance was greater than the sum of the strut thickness + polymer thick-
ness + drug, this strut was further classified as malapposed (panel D).
Figure 3. Malapposition. The metallic struts reflect all the light falling on their surface and produce a single hyperintense signal, which appears as intense glow (blooming), fol-
lowed by intense dorsal shadowing. To determine the malapposition state, the authors used the distance from the luminal surface of the strut to the vascular lumen contour. 
When this distance was greater than the total strut thickness (metal strut + polymer thickness + drug), plus a 20 m correction factor to correct for the actual location of the strut 
surface, it was classified as malapposed (middle panel), and the malapposition distance was computed for each individual strut (left panel). Malapposition was also quantified as 
the area in each frame in which it is identified along the treated segment (right panel; hatched region in red). BES: biolimus A9-eluting stent (BioMatrixTM); EES: everolimus-
eluting stent (XIENCE VTM).
Superficial  
blooming
Total strut 
thickness (metal 
strut + polymer 
thickness + drug)
0,20 μm
Dorsal shadowing Malapposition 
distance
Lumen
Individualized cutoff points to determine malapposition
 Strut Polymer Correction Cut-off point 
 thickness thickness fator 
SEB 120 μm 10 μm (parylene C) 20 μm 150 μm
SEE 81 μm 9 μm 20 μm 110 μm
Figure 4. Qualitative assessment of neointimal tissue. In A, the cross-sectional image 
illustrates a pattern of normal vascular healing, characterized by high-intensity and 
homogeneous neointimal optical appearance. In B, an example of peri-strut infiltrate 
between 4 and 7 o’clock, characterized as a well-defined and homogeneous region 
that promotes low reflection of the optical signal, with less intensity than that of the 
surrounding tissue, but without causing lumen attenuation (allows for viewing of pos-
terior structures). In C, an example of neoatherosclerosis, represented by lipid infiltra-
tion of neointimal tissue between 10 and 2 o’clock. Note significant attenuation of the 
optical signal, which prevents the visualization of the posterior structures in the re-
gion, including the stent struts.
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MatrixTM (n = 22) or the XIENCE VTM stent (n = 18). Of these, angio-
graphic restudy at 6 months with IVUS and OCT was performed in 
36 (90%) patients. After qualitative assessment of OCT images 
through core lab, a total of 26 patients were included for assessment 
of OCT outcomes (15 with BioMatrixTM and 11 with XIENCE VTM). 
A flowchart detailing the inclusion of the patients in the study is 
shown in Figure 5.
Table 1 shows the baseline demographic characteristics, while 
the angiographic and procedure variables are shown in Table 2. The 
mean age in both groups was 58.38 ± 8.15 years, and 50% of the pa-
tients included in the study were females. Stable angina was the pre-
dominant form of clinical presentation in both groups. There was a 
balanced distribution among the target vessels, and B2/C lesions ac-
counted for 42.3% of the treated lesions. The target-vessel reference 
diameter was 2.99 ± 0.38 mm and lesion length was 10.63 ± 4.39 
mm. Predilation of the lesions was performed in only five patients 
from each group, while the post-dilation was performed in 90% of 
cases in both groups, achieving a balloon-artery ratio of 1.13 ± 0.09.
OCT analysis results
From a total of 823 frames available for analysis (respecting the 
interval between frames of 0.6 mm), 75 frames were excluded from 
analysis for the following reasons: image with more than 45° of the 
circumference outside the field-of-view (n = 29 frames); presence of 
residual blood in significant amounts, preventing the visualization 
of the vessel intimal layer (n = 28 frames); and electronic artifacts (n 
= 18 frames). All 75 frames excluded were acquired using the first-
generation equipment TD-OCT. In the 748 frames analyzed, 7,725 
stent struts were evaluated individually. Table 3 shows the OCT anal-
ysis results.
There were no significant differences between the groups re-
garding the planar quantitative morphometric analysis in cross-sec-
tional level, as well as detailed analysis at strut level. Regarding the 
efficacy outcomes, both stent types showed marked antiprolifera-
tive potency, as shown by the small areas (0.56 ± 0.28 mm2 vs. 0.68 ± 
0.43 mm2; p = 0.41) and thickness (90.00 ± 32.75 m vs. 96.40 ± 35.01 
m; p = 0.64) of neointimal hyperplasia, which resulted in a small 
Patients with de novo coronary lesions included  
between 2011-2012
n = 40
BioMatrixTM (BES)
n = 22
XIENCE VTM (EES)
n = 18
Angiographic and OCT results at six months obtained in 90% of the patients (36/40)
r0OF QBUJFOU SFGVTFE BOHJPHSB 
phic follow-up
r4JY QBUJFOUT IBE JOBEFRVBUF
OCT images
r5ISFFQBUJFOUTEJEOPUIBWF0$5
performed
r'PVS QBUJFOUT XJUI 0$5 JNBHFT
JOBEFRVBUFGPSBOBMZTJT
OCT at six months with images 
adequate for analysis (n = 15)
OCT at six months with images 
adequate for analysis (n = 11)
Figure 5. Study flowchart. Inclusion of patients in the study, identification of group to which they were allocated, and number of patients undergoing evaluation with optical 
coherence tomography (OCT). BES: A9-biolimus-eluting stent (BioMatrixTM); EES: everolimus-eluting stent (XIENCE VTM).
Table 1
Baseline demographic characteristics.
Variables
BioMatrixTM  
(n = 15)
XIENCE VTM  
(n = 11) p-value
Age, years 56.93 ± 9.52 60.36 ± 5.64 0.30
Female gender, n (%) 10 (66.7) 3 (27.3) 0.11
Arterial hypertension, n (%) 14 (93.3) 10 (90.9) > 0.99
Dyslipidemia, n (%) 9 (60.0) 9 (81.8) 0.40
History of smoking, n (%) 13 (86.7) 6 (54.5) 0.10
Current smoking 4 (26.7) 3 (27.3)
Previous infarction, n (%) 7 (46.7) 4 (36.4) 0.70
Previous PCI, n (%) 1 (6.7) 0 > 0.99
Previous CABG, n (%) 0 0 > 0.99
Clinical presentation, n (%) 0.63
Silent ischemia 1 (6.7) 0
Stable angina 12 (80.0) 10 (90.9)
Unstable angina 2 (13.3) 1 (9.1)
PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft surgery.
Table 2
Angiographic and procedural characteristics.
Variables
BioMatrixTM 
(n = 15)
XIENCE VTM 
(n = 11) p-value
Target vessel, n (%) 0.44
LAD 4 (26.7) 3 (27.3)
LCx 5 (33.3) 6 (54.5)
RCA 6 (40.0) 2 (18.2)
Moderate/severe calcification, n (%) 3 (20.0) 4 (36.4) 0.41
Lesion classification, n (%) 0.25
A/B1 9 (60.0) 6 (54.5)
B2/C 6 (40.0) 5 (45.5)
Reference vessel diameter, mm 3.05 ± 0.35 2.90 ± 0.40 0.32
Lesion length, mm 10.90 ± 3.66 10.24 ± 5.38 0.71
Minimal luminal diameter, mm 0.91 ± 0.47 1.01 ± 0.36 0.58
Diameter stenosis, % 69.86 ± 13.71 66.71 ± 11.65 0.55
Pre-dilation, n (%) 5 (33.3) 5 (45.5) 0.69
Nominal stent diameter, mm 3.17 ± 0.24 3.14 ± 0.32 0.79
Nominal stent length, mm 20.80 ± 4.59 18.55 ± 5.68 0.27
Post-dilation, n (%) 14 (93.3) 10 (90.9) > 0.99
Balloon-artery ratio 1.11 ± 0.05 1.15 ± 0.11 0.35
LAD: left anterior descending artery; LCx: left circumflex artery; RCA: right coronary artery.
 D. Chamié et al. / Rev Bras Cardiol Invasiva. 2015;23(1):28-37 33
percentage of stent obstruction in both groups (8.44% ± 5.10% vs. 
9.21% ± 6.36%; p = 0.74). It is noteworthy that, despite the small 
amount of neointimal tissue formed at the end of the 6 month peri-
od, its distribution was homogenous throughout the treated seg-
ment (Fig. 6). In fact, the percentage of uncovered struts per patient 
(primary surrogate safety endpoint) was low and similar between 
the BioMatrixTM and XIENCE VTM groups (2.10% ± 3.60% vs. 2.46% ± 
2.15%; p = 0.77). Similarly, the incidence of malapposed struts was 
very low and similar in both groups (0.48% ± 1.48% vs. 0.44% ± 1.05%, 
p = 0.94) as well as the distance of malapposition of each individual 
strut to the vessel wall (235.00 ± 247.99 m vs. 230.00 ± 306.43 m; 
p = 0.98). Notably, the maximum longitudinal length of segments 
with uncovered (1.09 ± 1.59 mm vs. 1.35 ± 0.93 mm; p = 0.64) or 
malapposed struts (0.43 ± 1.18 mm vs. 0.31 ± 0.67 mm, p = 0.75) was 
small and similar between the groups. Figure 7 shows examples of 
good healing profile of the two types of stents.
In the analysis on the quality of neointimal tissue formed on the 
stents, the finding of peri-strut infiltrate was relatively rare, occur-
ring in 15.53% of the frames analyzed in the BioMatrixTM group and 
in 11.70% of the frames analyzed in the XIENCE VTM group (p = 0.68). 
Neoatherosclerosis was observed in only one stent in each group.
Clinical outcomes
There were no cases of death or infarction during the 1-year fol-
low-up. There were two target-lesion revascularizations – one in 
each group. One patient from the XIENCE VTM group had stable an-
gina and at the time of restudy at 6 months had severe in-stent re-
stenosis, with neoatherosclerosis findings on OCT, and thus was 
submitted to target-lesion revascularization. Another patient – from 
the BioMatrixTM group – also had stable angina at the 6-month re-
study, which showed severe restenosis in the distal border of the 
previously implanted stent and was thus submitted to a new revas-
cularization.
Discussion
Debates about DES safety are recurrent issues, but are still rele-
vant. The present study used OCT to assess the antiproliferative ef-
ficacy of two types of second-generation DES, using surrogate 
endpoints to infer their safety in the medium term. The main find-
ings were as follows: the incidence of uncovered or malapposed 
struts was low and similar in both groups after 6 months; the antipro-
liferative efficacy was maintained in both groups, with minimal 
neointimal formation, evenly distributed along the treated seg-
ments, resulting in low percentage of obstruction; both DES, utiliz-
ing different technologies, promoted “healthy” optical healing 
aspect, with low incidence of peri-strut infiltrate.
Although the DES were successful in achieving their primary 
purpose of minimizing neointimal formation and reducing rates of 
restenosis and new revascularizations, the excess occurrence of late 
and very-late thrombotic events in these devices triggered a warn-
ing sign about their safety in the long-term. Although late stent 
thrombosis is a multifactorial phenomenon, it has been shown that 
the polymers used in DES to carry and control the release of antipro-
liferative agents locally in the vascular wall play a key role in the 
genesis and perpetuation of local inflammatory processes, poten-
tially leading to the formation of late vascular remodeling and de-
layed healing.12,14,16
Aiming to minimize the deleterious effects of polymers found in 
first-generation DES, a series of modifications has been promoted in 
Table 3
Optical coherence tomography results.
Variables BioMatrixTM (n = 15) XIENCE VTM (n = 11) p-value
Cross-section
Total frames analyzed 465 284 0.20
Number of frames analyzed per patient 31.00 ± 10.50 25.72 ± 9.22 0.20
Lumen
Mean area, mm2 7.43 ± 3.23 6.73 ± 1.64 0.52
Minimal area, mm2 6.10 ± 5.08 2.91 ± 1.73 0.31
Mean diameter, mm2 3.00 ± 0.66 2.89 ± 0.36 0.64
Eccentricity index 0.13 ± 0.03 0.14 ± 0.03 0.35
Volume, mm3 159.65 ± 88.48 118.0.6 ± 47.60 0.17
Stent
Mean area, mm2 7.84 ± 2.99 7.30 ± 1.70 0.60
Minimal area, mm2 6.63 ± 2.53 6.22 ± 1.45 0.64
Mean diameter, mm 3.10 ± 0.60 3.02 ± 0.10 0.72
Eccentricity index 0.09 ± 0.02 0.09 ± 0.03 0.88
Volume, mm3 166.96 ± 82.83 128.61 ± 54.38 0.19
Intimal hyperplasia 
Area, mm2 0.56 ± 0.28 0.68 ± 0.43 0.41
Volume, mm3 9.97 ± 4.45 11.69 ± 11.24 0.60
Volume obstruction, % 8.44 ± 5.10 9.21 ± 6.36 0.74
Struts
Total struts analyzed 4,478 3,247 0.94
Number of struts analyzed per patient 298.53 ± 111.83 294.54 ± 151.00 0.94
Number of struts analyzed per frame 9.71 ± 1.84 11.04 ± 2.09 0.10
Uncovered struts per patient, % 2.10 ± 3.60 2.46 ± 2.15 0.77
Frames with > 30% uncovered struts per patient, % 1.51 ± 3.37 1.66 ± 3.47 0.91
Maximum length of segments with uncovered struts, mm 1.09 ± 1.59 1.35 ± 0.93 0.64
Malapposed struts per patient, % 0.48 ± 1.48 0.44 ± 1.05 0.94
Distance of malapposition, m 235.00 ± 247.99 230.00 ± 306.43 0.98
Frames with > 30% malapposed struts per patient, % 0.56 ± 2.19 0.48 ± 1.59 0.91
Maximum length of segments with malapposed struts, mm 0.43 ± 1.18 0.31 ± 0.67 0.75
Intimal hyperplasia thickness on covered struts, m 90.00 ± 32.95 96.40 ± 35.01 0.64
Stents with peri-strut infiltrate, n (%) 8 (53.3%) 3 (27.3%) 0.25
Frames with peri-strut infiltrate per patient, % 15.53 ± 20.77 11.70 ± 27.51 0.68
Stents with neoatherosclerosis, n (%) 1 (6.6%) 1 (9.1%) > 0.99
Frames with neoatherosclerosis per patient, % 0.32 ± 1.26 2.34 ± 7.78 0.32
34 D. Chamié et al. / Rev Bras Cardiol Invasiva. 2015;23(1):28-37
the design of new generations of DES. Among these modifications, 
the authors highlight the use of new metal alloys, with thinner 
struts; more biocompatible polymers, applied only to the abluminal 
surface of the struts (thus reducing their thickness); bioabsorbable 
polymers; non-polymeric drug carrier technology; and even totally 
bioabsorbable stents.17
Incorporating some of these technological developments, the 
BioMatrixTM stent has a bioabsorbable PLA polymer, applied to the 
abluminal surface of the stent platform’s stainless steel struts, which 
carries and releases biolimus A9. The benefits of this new second-
generation DES were demonstrated in the Limus Eluted from A Du-
rable versus ERodable Stent coating (LEADERS) trial, which 
conducted a randomized comparison of the clinical outcomes of the 
BioMatrixTM stent with the first-generation DES CYPHERTM, a sirolim-
us-eluting stent released through a durable polymer. After 5 years, 
the group of patients treated with BioMatrixTM stent showed a trend 
to a lower incidence of major adverse cardiac events (22.3% vs. 26.1%; 
p = 0.071), in addition to a significant reduction in rates of late stent 
thrombosis after the first year (0.66% vs. 2.5%; p = 0.003).27 The OCT 
sub-analysis of this study showed a better healing profile with the 
BioMatrixTM stent, with a lower percentage of uncovered struts when 
compared with the CYPHERTM stent (0.6% vs. 2.1%, p = 0.04) at the end 
of 9 months.28
Similarly, the second-generation DES XIENCE VTM was also com-
pared to the CYPHERTM stent in the randomized trial Scandinavian 
Organization for Randomized Trials with Clinical Outcome IV (SORT 
OUT IV). At the end of 9 months, the occurrence of the primary end-
point (cardiac death, myocardial infarction, definitive stent throm-
bosis, and target-vessel revascularization) was similar between the 
two types of DES (4.9% vs. 5.2%, p for non-inferiority = 0.01).29 These 
Figure 6. Dispersed neointimal topography. Neointimal tissue thickness was estimated around the 360° of circumference in each frame analyzed along the treated segment, and 
its distribution is shown in the circumferential and longitudinal directions of each evaluated stent. The graphs represent the stent cut longitudinally along the zero angle of the 
vessel circumference and arranged on a flat surface. The horizontal axis represents the stent length and the vertical axis, the 360° of its circumference. Neointimal tissue amount 
is represented by a color map, according to lesser (red) or greater (blue) thickness. It can be observed that both types of stents have low neointimal tissue thickness, with homo-
geneous distribution. Only two cases – one in each group – showed greater focal accumulation of neointimal tissue, identified by blue regions. These two patients had severe 
intra-segment restenosis and underwent new revascularization.
Figure 7. Healing profile of the stents. Three-dimensional reconstructions in the lon-
gitudinal direction of the BioMatrixTM and XIENCE VTM stents, illustrating the healing 
profile of these devices after 6 months. Note the presence of a thin neointimal tissue 
layer covering the entire treated segment, with a minimum percentage of uncovered 
struts.
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results were maintained until the end of the 2-year follow-up (8.3% 
vs. 8.7%; p = 0.66).30 Importantly, the XIENCE VTM stent, which simi-
larly to the CYPHERTM stent has durable polymer, but is thinner and 
more biocompatible, showed a strong trend toward a lower inci-
dence of definitive stent thrombosis at 9 months (0.1% vs. 0.7%, p = 
0.05),29 which was significantly confirmed at the end of 2 years (0.2% 
vs. 0.9%; p = 0.02).30
After verifying the non-inferiority of the second-generation DES 
when compared to first-generation DES regarding their antiprolif-
erative efficiency, but featuring a better safety profile,31 it was not 
long before the first comparisons between second-generation DES 
started to appear.
The Comparison of the Everolimus Eluting with the Biolimus A9 
Eluting Stent (COMPARE-II) trial compared, in a randomized manner 
(2:1), 2,707 patients for treatment with NoboriTM stents (n = 1,795; 
Terumo, Tokyo, Japan), which, similarly to BioMatrixTM stents, re-
lease biolimus A9 through a bioabsorbable polymer, or with everoli-
mus-eluting stents through a durable fluoropolymer (XIENCE VTM or 
XIENCE PRIMETM; n = 912). The occurrence of the primary endpoint 
(cardiac death, nonfatal myocardial infarction, and target-vessel re-
vascularization guided by ischemia) at 12 months was similar in 
both groups (NoboriTM: 5.2% vs. XIENCE VTM: 4.8%; p for non-inferior-
ity < 0.0001).32 These results are echoed in the OCT evaluation of 
these two stent types performed by Tada et al., who found no sig-
nificant differences regarding the percentage of strut coverage be-
tween the second-generation DES NoboriTM and XIENCE VTM (OR = 
1.54; 95%CI 0.63-3.79; p = 0.34) after 6 to 8 months.
The present study confirmed the excellent healing profile of 
XIENCE VTM and BioMatrixTM stents, which demonstrated potent 
suppression in neointimal formation intensity without affecting the 
healing profile, as demonstrated by the low percentage of uncovered 
struts. However, a longer follow-up is required to assess the poten-
tial benefits of DES with durable polymers.
Evolution in the evaluation of new drug-eluting stents  
and the contribution of optical coherence tomography
The evolution of invasive imaging methods has coincided with 
technological advances in interventional cardiology. Throughout 
history, intravascular imaging methods have contributed to the un-
derstanding of the mechanism of action in different devices, helping 
to understand possible failure mechanisms and providing for tech-
nological advancement.
Historically, the late performance of a coronary stent was evalu-
ated for its efficacy in suppressing neointimal tissue formation – 
of ten evaluated by late luminal loss at angiography and 
quantification, by IVUS, of neointimal hyperplasia volume and the 
degree to which this tissue obstructs stent area (the percentage of 
obstruction). However, the demonstration, through histopathologi-
cal studies, that the absence or delay in stent strut healing was 
among the most powerful pathological predictors for the occur-
rence of late thrombosis in these devices13,16 induced reflection 
about the in vivo evaluation of coronary stents. The focus was no 
longer only the assessment of the antiproliferative stent potency, 
but also the quantitation of morphometric markers indicative of 
safety. Thus, the percentage of coverage and apposition of coronary 
stent struts started to be used as a primary endpoint in a number of 
randomized studies designed to evaluate the performance of differ-
ent DES over variable periods.33
While BMS usually develop a circumferential coverage of neointi-
mal tissue with a mean thickness of 500 m (late luminal loss of ap-
proximately 1 mm) – easily identified and quantified by angiography 
and IVUS – DES show a delayed and even null hyperplastic response 
that is so intense that their struts are often covered by a thin tissue 
layer, whose thickness is well below the detection limits of angiog-
raphy and IVUS. Due to its high axial resolution (ten times greater 
than that provided by IVUS), OCT was demonstrated to be more sen-
sitive and accurate than the IVUS to identify coverage and malap-
position of stent struts,34-36 showing good correlation with 
histological assessment18,36-38 and high reproducibility.18,38 Therefore, 
OCT allows for the assessment of complex stent-vessel interaction in 
vivo with an unprecedented level of detail, and thus became the 
standard imaging modality for vascular response assessment after 
stent implantation in a number of randomized studies.33 In the pres-
ent study, the mean thickness of the neointimal tissue formed at the 
end of 6 months was less than 100 Rm and was below the detection 
limits of the IVUS.
In addition to the abovementioned accurate quantitative assess-
ment, OCT also allows for the identification of the quality of the neo-
intimal tissue formed. At the beginning of DES evaluations with OCT, 
it was not rare to observe areas of low optical signal intensity in the 
neointimal tissue around the stent struts. These findings, known as 
peri-strut infiltrates (or PLIA, peri-strut low intensity areas) showed 
correspondence, at the histological findings, with hypocellular re-
gions and the presence of fibrinoid material and proteoglycans, sur-
rounded by a polymorphic healing response with macrophages and 
lymphocytes.25 A pathological study carried out by van Beusekom et 
al. showed the presence of acellular areas after first-generation DES 
implantation, which did not exist with BMS.39 These findings were 
confirmed in vivo in the assessment of 36 stents, in which peri-strut 
infiltrates were more frequently identified in DES (65%) than in BMS 
(19%; p < 0.001), suggesting a local adverse reaction to the drug and/
or polymer.25 Neoatherosclerosis is a phenomenon that refers to the 
formation of new atherosclerotic plaque inside an already-formed 
neointima. The degeneration of a normal neointima, with the devel-
opment of vulnerable plaques and their eventual rupture, has been 
recently identified as a cause of late stent failure – again, more fre-
quently identified after DES implantation.40 In the present study, the 
incidence of peri-strut infiltrate was lower than that observed after 
first-generation DES implantation, suggesting, in theory, a more be-
nign vascular response after second-generation DES implantation. 
The actual clinical impact of these findings remains to be investi-
gated in larger studies with a longer follow-up period. In the present 
population, the incidence of neoatherosclerosis was low, represent-
ed by one case in each group. However, it was associated with more 
exacerbated neointimal proliferation in one case, which required 
revascularization.
Limitations
Some limitations of the present study are worth mentioning. 
First, although the included population provided enough data (749 
frames and 7,725 struts analyzed) for evaluation of surrogate end-
points of efficacy and safety by OCT, the number of patients included 
is insufficient to assess the clinical impact of the findings on OCT. 
Second, non-performance of the OCT after the index procedure pre-
vents a temporal classification of observed malappositions; it is not 
possible to determine whether a malapposition identified at 6 
months is only the residual effect of an acute malapposition, or 
whether it was acquired later. However, the low incidence and mag-
nitude of the malappositions, observed in the context of favorable 
stent healing, suggest that the few malappositions observed in this 
study do not represent unfavorable local vascular reactions. Third, 
the 6-month evaluation period appears to be a short time to detect 
potential differences between the two stents evaluated. It is un-
known whether the favorable vascular responses observed in the 
present study will remain in the long-term follow-up. Fourth, the 
population included in this analysis consisted predominantly of sta-
ble patients without diabetes and with relatively short lesions in 
larger vessels. This selection was aimed to minimize the inclusion of 
patients with more advanced disease, which could impact the as-
sessment of endothelial function – one of the primary BIOACTIVE 
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study endpoints. Thus, extrapolation of the results shown here to 
more complex populations should be performed with caution.
Conclusions
The second-generation drug-eluting stents BioMatrixTM and 
XIENCE  VTM showed favorable vascular response after 6 months. 
These two types of drug-eluting stents demonstrated excellent effi-
cacy profiles, with effective suppression of neointimal formation and 
low percentage of in-stent obstruction, without causing delay in strut 
coverage, as shown by the low and comparable rates of non-covered 
and malapposed struts. In addition, the healing quality was also favor-
able, with reduced rates of peri-strut infiltrate and neoatherosclerosis.
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